Medicare Enrolled
Dr. Samuel Myrick, MD
Medical Oncology · Ocala, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Myrick from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Myrick? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Myrick
Dr. Samuel Myrick is a medical oncology in Ocala, FL, with 20 years in practice. Based on federal Medicare data, Dr. Myrick performed 90,343 Medicare services across 3,265 unique beneficiaries.
Between the years covered by Open Payments, Dr. Myrick received a total of $28,869 from 103 pharmaceutical and/or device companies across 1344 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Myrick is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 27% volume in FL$ $28,869 industry payments
Medicare Practice Summary
Medicare Utilization ↗90,343
Medicare services
Top 27% in FL for medical oncology
3,265
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,517 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Zarxio) for white blood cells | 25,560 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 24,090 | $2 | $21 |
| Pembrolizumab injection (Keytruda) | 9,400 | $43 | $147 |
| Iron infusion (Monoferric) | 7,600 | $17 | $75 |
| Denosumab injection (Prolia/Xgeva) | 5,280 | $19 | $70 |
| Anti-nausea injection (fosaprepitant) | 5,100 | $0 | $6 |
| Immune globulin infusion (Octagam) | 3,662 | $34 | $251 |
| Complete blood count (CBC) with differential | 880 | $8 | $35 |
| Dexamethasone injection (steroid) | 880 | $0 | $1 |
| Blood draw (venipuncture) | 841 | $8 | $19 |
| Comprehensive metabolic blood panel | 764 | $10 | $62 |
| Epoetin alfa injection (Retacrit) for anemia | 690 | $6 | $30 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 600 | $92 | $879 |
| Anti-nausea injection (Aloxi/palonosetron) | 550 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 420 | $0 | $25 |
| Drug injection, under skin or into muscle | 380 | $11 | $93 |
| Office visit, established patient (30-39 min) | 352 | $94 | $224 |
| Injection of additional new drug or substance into vein | 336 | $12 | $105 |
| Office visit, established patient (20-29 min) | 329 | $64 | $149 |
| Administration of chemotherapy into vein, 1 hour or less | 198 | $99 | $686 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 184 | $47 | $304 |
| Ferritin level test (iron stores) | 180 | $13 | $58 |
| Iron level test | 179 | $6 | $26 |
| Iron binding capacity test | 179 | $9 | $34 |
| Vitamin B-12 level test | 128 | $15 | $74 |
| Folic acid level test | 123 | $14 | $71 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 105 | $16 | $97 |
| Lactate dehydrogenase (enzyme) level | 99 | $6 | $30 |
| Hospital follow-up visit, moderate complexity | 93 | $64 | $157 |
| Injection, diphenhydramine hcl, up to 50 mg | 91 | $1 | $7 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 84 | $1 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 78 | $24 | $249 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 73 | $1 | $19 |
| Measurement of substance using immunoassay technique | 68 | $17 | $181 |
| Nephelometry, test method using light | 68 | $13 | $176 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $22 | $152 |
| Administration of additional new drug or substance into vein, 1 hour or less | 55 | $50 | $334 |
| PSA test (prostate cancer screening) | 54 | $18 | $91 |
| Infusion, normal saline solution , 1000 cc | 50 | $2 | $19 |
| Irrigation of implanted venous access drug delivery device | 47 | $17 | $111 |
| Antibody identification test, platelet associated immunoglobulin assay | 45 | $12 | $155 |
| New patient office visit (45-59 min) | 45 | $129 | $343 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $56 | $205 |
| Infusion into a vein for hydration, each additional hour | 39 | $10 | $73 |
| Administration of chemotherapy into vein, each additional hour | 35 | $21 | $156 |
| Collection of blood sample from implanted device | 34 | $19 | $64 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 34 | $20 | $124 |
| Measurement of immunoglobulin light chains | 30 | $17 | $60 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 26 | $65 | $214 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 21 | $1,205 | $4,120 |
| Injection of drug or substance into vein | 18 | $29 | $240 |
| Drawing of blood for a medical problem | 17 | $75 | $251 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 16 | $410 | $638 |
| Carcinoembryonic antigen (cea) protein level | 14 | $19 | $96 |
| Initial hospital admission, moderate complexity | 12 | $106 | $297 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.1% high complexity
81.6% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$28,869
Total received (2018-2024)
Avg $4,124/year across 7 years
Top 19% in FL for medical oncology
103
Companies
1,344
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,725 (92.6%)
Other
Charitable contributions, space rental, and other categories
$1,423 (4.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$722 (2.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$6,574
2023$4,411
2022$4,349
2021$3,612
2020$2,443
2019$4,082
2018$3,399
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,627
Janssen Biotech, Inc.
$1,756
PFIZER INC.
$1,679
AstraZeneca Pharmaceuticals LP
$1,498
Amgen Inc.
$1,170
E.R. Squibb & Sons, L.L.C.
$1,092
Astellas Pharma US Inc
$1,015
Incyte Corporation
$786
Lilly USA, LLC
$755
Celgene Corporation
$741
Seagen Inc.
$737
Merck Sharp & Dohme Corporation
$702
Merck Sharp & Dohme LLC
$675
Daiichi Sankyo Inc.
$634
Ipsen Biopharmaceuticals, Inc
$575
GENZYME CORPORATION
$535
GlaxoSmithKline, LLC.
$534
Genentech USA, Inc.
$510
Bayer HealthCare Pharmaceuticals Inc.
$488
Takeda Pharmaceuticals U.S.A., Inc.
$481
Kite Pharma, Inc.
$444
Regeneron Healthcare Solutions, Inc.
$425
Pharmacyclics LLC, An AbbVie Company
$389
EMD Serono, Inc.
$376
Genmab U.S., Inc.
$352
Seattle Genetics, Inc.
$352
Eisai Inc.
$307
Rigel Pharmaceuticals, Inc.
$297
Octapharma USA, Inc.
$295
Boehringer Ingelheim Pharmaceuticals, Inc.
$274
JAZZ PHARMACEUTICALS INC.
$273
EISAI INC.
$267
TESARO, Inc.
$255
Puma Biotechnology, Inc.
$254
Gilead Sciences, Inc.
$227
SERVIER PHARMACEUTICALS LLC
$197
Karyopharm Therapeutics Inc.
$191
Alexion Pharmaceuticals, Inc.
$190
Bayer Healthcare Pharmaceuticals Inc.
$189
Janssen Scientific Affairs, LLC
$183
Jazz Pharmaceuticals Inc.
$181
ARRAY BIOPHARMA INC
$168
Mirati Therapeutics, Inc.
$164
ABBVIE INC.
$158
Clovis Oncology, Inc.
$148
G1 Therapeutics, Inc.
$137
Stemline Therapeutics Inc.
$132
BeiGene USA, Inc.
$131
Pharmacosmos Therapeutics Inc.
$127
Dova Pharmaceuticals
$126
MorphoSys, US Inc.
$117
Foundation Medicine, Inc.
$117
TerSera Therapeutics LLC
$102
Ethicon US, LLC
$101
CTI BioPharma Corp.
$97
Novocure Inc.
$89
PharmaEssentia USA Corporation
$85
Apellis Pharmaceuticals, Inc.
$83
Agios Pharmaceuticals, Inc.
$80
Heron Therapeutics, Inc.
$79
Servier Pharmaceuticals LLC
$78
Deciphera Pharmaceuticals Inc.
$74
Pharmacyclics LLC, an AbbVie Company
$74
PUMA BIOTECHNOLOGY, INC.
$71
TAIHO ONCOLOGY, INC.
$68
TG THERAPEUTICS, INC.
$65
MEDIVATION FIELD SOLUTIONS LLC
$63
CSL Behring
$63
SOBI, INC
$60
Taiho Oncology, Inc.
$60
Dendreon Pharmaceuticals LLC
$60
ADC Therapeutics America, Inc.
$57
Exelixis Inc.
$55
Sun Pharmaceutical Industries Inc.
$53
Epizyme, Inc.,
$52
Aveo Pharmaceuticals, Inc.
$51
AbbVie Inc.
$48
Blueprint Medicines Corporation
$48
Astellas Pharma Global Development
$48
Global Blood Therapeutics, Inc.
$48
Array BioPharma Inc.
$39
Immunocore Limited
$36
Secura Bio, Inc.
$36
Kyowa Kirin, Inc.
$33
AVEO Pharmaceuticals, Inc.
$31
Teva Pharmaceuticals USA, Inc.
$30
Helsinn Therapeutics (U.S.), Inc.
$25
Fennec Pharmaceuticals, Inc.
$24
Tempus AI, Inc
$23
TG Therapeutics, Inc.
$23
Acrotech Biopharma Inc.
$20
AbbVie, Inc.
$20
Medtronic, Inc.
$20
Advanced Accelerator Applications
$19
Lexicon Pharmaceuticals, Inc.
$19
Geron Corporation
$19
TOLMAR Pharmaceuticals, Inc.
$18
Emmaus Medical, Inc.
$17
Alnylam Pharmaceuticals Inc.
$17
Grifols USA, LLC
$16
Collegium Pharmaceutical, Inc.
$15
Coherus Biosciences Inc.
$14
GE HEALTHCARE
$10
Top 3 companies account for 21.0% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AUGTYRO · AYVAKIT · Afstyla · Alecensa · Aliqopa · Aranesp · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · CERTUS 140 MICROWAVE ABLATION SYSTEM · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · Creon · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELITEK · ELREXFIO · EMPRINT · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · EVENITY · EXKIVITY · Empaveli · Endari · Enhertu · Epkinly · Erleada · FARYDAK · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · GAZYVA · GILOTRIF · GIVLAARI · Gamunex-C · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFUGEM · INJECTAFER · INLYTA · INREBIC · Imbruvica · Inrebic · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · Lutathera · MEKINIST · MEKTOVI · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO (sonidegib) capsules · OJJAARA · ONIVYDE · OPDIVO · OPDUALAG · OXBRYTA · Oncaspar · Onivyde · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSTATE CANCER - DISEASE · PROVENGE · PYRUKYND · Padcev · Pedmark · Perjeta · Polivy · Pomalyst · Prolia · QINLOCK · Quzyttir · REBLOZYL · RECOTHROM · RETEVMO · RYBREVANT · RYTELO · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · TAFINLAR · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTAMPZA · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA (abiraterone acetate) · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $32 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
6
Per 100K population
1.5
County median income
$58,535
Nearest hospital
ADVENTHEALTH OCALA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Myrick is a mixed practice specialist, with above-average Medicare volume (top 27% in FL), and high industry engagement (low-engagement, top 19%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Myrick experienced with filgrastim injection (zarxio) for white blood cells?
Based on Medicare claims data, Dr. Myrick performed 25,560 filgrastim injection (zarxio) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Myrick receive payments from pharmaceutical companies?
Yes. Dr. Myrick received a total of $28,869 from 103 companies across 1,344 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Myrick's costs compare to other medical oncologys in Ocala?
Dr. Myrick's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Myrick) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Ocala
Browse medical oncologys in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology